Benitec Biopharma Ltd ADR (BNTC) earnings
In the quarter ended June 2026, Benitec Biopharma Ltd ADR had revenue of —.
On September 14, 2026 it reported EPS of -0.26 against an estimate of -0.26 (matched).
The next report is expected on Friday, November 13, 2026, with EPS expected around -0.28.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Fri Nov 13, 2026 | — | -0.28 | — |
| Last | Mon Sep 14, 2026 | — | -0.26 | -0.26 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Benitec Biopharma Ltd ADR's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | — | — | — | — | — | 2026-09-14 |
| Mar 31, 2026 | $0 | — | -0.24 | — | — | 2026-05-14 |
| Dec 31, 2025 | $0 | — | -0.26 | — | — | 2026-02-12 |
| Sep 30, 2025 | $0 | — | -0.22 | — | — | 2025-11-14 |
| Jun 30, 2025 | — | — | -0.21 | — | — | 2025-09-22 |
| Mar 31, 2025 | $0 | — | -0.38 | — | — | 2025-05-14 |
| Dec 31, 2024 | $0 | — | -0.26 | — | — | 2025-02-14 |
| Sep 30, 2024 | $0 | — | -0.18 | — | — | 2024-11-14 |
| Jun 30, 2024 | $0 | — | — | — | — | 2024-09-26 |
| Mar 31, 2024 | $0 | — | -0.23 | — | — | 2024-05-13 |
| Dec 31, 2023 | $0 | — | -1.32 | — | — | 2024-02-13 |
| Sep 30, 2023 | $0 | — | -1.52 | — | — | 2023-11-13 |
Questions
When does Benitec Biopharma Ltd ADR report earnings?
Benitec Biopharma Ltd ADR's next earnings report is expected on November 13, 2026.
How did Benitec Biopharma Ltd ADR do last quarter?
In the quarter ended June 2026, Benitec Biopharma Ltd ADR had revenue of —.
From Benitec Biopharma Ltd ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.